Ramaswami, Ramya <br/><br/>
Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.  [electronic resource] 

 -  Future oncology (London, England)  Feb 2014 
 - 363-76 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon.13.210  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--economics<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Drug Costs<br/>Drug Resistance, Neoplasm<br/>England<br/>Female<br/>Furans--economics<br/>Healthcare Financing<br/>Humans<br/>Kaplan-Meier Estimate<br/>Ketones--economics<br/>Proportional Hazards Models<br/>Treatment Outcome